FMP

FMP

Enter

VRNA - Verona Pharma plc

Valuation of Verona Pharma plc(VRNA), Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercial

photo-url-https://financialmodelingprep.com/image-stock/VRNA.png

Verona Pharma plc

VRNA

NASDAQ

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

15.72 USD

-0.38 (-2.42%)

Valuation Date:

Apr 19, 2024 4:00 PM

Share Price on Valuation Date

$15.72

Stock Beta

0.415

Shares Outstanding

80442011

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep